Last reviewed · How we verify
NCT07057726
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection by Single Intravenous Infusion in Healthy Chinese Subjects
Phase 1 trial testing SSS39 in Safety and Tolerability in Healthy Volunteers in 48 participants. Enrolling by invitation.
1 October 2025
Quick facts
| Lead sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
|---|---|
| Phase | Phase 1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 48 |
| Start date | 9 October 2024 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
Conditions studied
- Safety and Tolerability in Healthy Volunteers — all drugs for Safety and Tolerability in Healthy Volunteers →
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD. — full company profile →
Who can join
Adults 18 to 45, any sex, with Safety and Tolerability in Healthy Volunteers. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To evaluate the safety and tolerance of SSSS55
Time frame: Day 50
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Sponsor's own description
To evaluate the safety, tolerability, and pharmacokinetics of SSS39 injection in healthy Chinese subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07057726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Safety and Tolerability in Healthy Volunteers
Currently open trials in the same condition.
- NCT06894875 — Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance · NA · recruiting
Other Shenyang Sunshine Pharmaceutical Co., LTD. trials
Trials by the same sponsor.
- NCT07487545 — Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via S · Phase 1 · not yet recruiting
- NCT07445308 — The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NM · Phase 1, PHASE2 · not yet recruiting
- NCT07171606 — A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients · Phase 2 · recruiting
- NCT07038005 — A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT07022002 — SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07057726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Sunshine Pharmaceutical Co., LTD.
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07057726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing